Sign In
Buy AMPE
$0.183
+0 (+0%)
At Close: Jun 03, 2026
Filled jobs fall 0.1 per cent: Aus shares close 0.1% higher
07:08am, Wednesday, 10'th Jun 2020
10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December and M
What's Opthea eyeing now that it has two successful trials under its belt? - Stockhead
03:44am, Wednesday, 10'th Jun 2020
Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema
Opthea (ASX:OPT) reports positive trial results: Aus shares 0.5% higher at noon
02:49am, Wednesday, 10'th Jun 2020
10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic M
Opthea's done it again: Its drug passed its DME clinical trial - Stockhead
12:16am, Wednesday, 10'th Jun 2020
Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient ph
Ampio Provides Update on COVID-19 Program
12:00pm, Friday, 22'nd May 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program
What You Must Know About Ampio Pharmaceuticals, Inc.'s (NYSEMKT:AMPE) Beta Value
10:45am, Thursday, 21'st May 2020
If you're interested in Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE), then you might want to consider its beta (a...
Placenta Growth Factor Pipeline Review, H1 2020: Companies Involved in Therapeutics Development - ResearchAndMarkets.com
12:00am, Thursday, 21'st May 2020
The
Ampio Reports Acceptance Of Publication On The Potential Benefits Of Nebulized Ampion For COVID-19 Coronavirus Patients
12:24pm, Monday, 11'th May 2020Ampio Pharma Reports Acceptance Of Publication On Potential Benefits Of Nebulized Ampion For Coronavirus Patients
12:21pm, Monday, 11'th May 2020Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampion™ for COVID-19 Patients
12:00pm, Monday, 11'th May 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development of immunology based therapies for prevalent inflammatory conditions, today announced a manuscr
Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampion™ for ...
12:00am, Monday, 11'th May 2020Global Macular Edema Therapeutics Market 2020 Segmentation Analysis, Key Players, Industry Share and Forecast by 2025
01:29pm, Sunday, 03'rd May 2020
May 03, 2020 (CDN Newswire via Comtex) --
A recent comprehensive study titled Global Macular Edema Therapeutics Market 2020 by Company, Regions, Type and...
Diabetic Retinopathy Market by Type, Treatment, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com
11:16am, Friday, 01'st May 2020
The "Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
